Classification of intestinal T‐cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten statusInvivoscribe Marketing2021-02-11T19:57:34-08:00November 22nd, 2020|Read more
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality TestingInvivoscribe Marketing2021-02-17T18:10:07-08:00November 17th, 2020|Read more
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myelomaInvivoscribe Marketing2021-02-11T20:05:42-08:00October 30th, 2020|Read more
Plasticity of the human IgM repertoire in response to long‐term spaceflightInvivoscribe Marketing2021-02-11T20:09:45-08:00October 13th, 2020|Read more
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapyInvivoscribe Marketing2021-02-11T20:11:02-08:00October 8th, 2020|Read more
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in JapanInvivoscribe Marketing2021-02-26T19:11:48-08:00November 19th, 2018|Read more
Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)Invivoscribe Marketing2021-02-26T19:12:02-08:00September 27th, 2018|Read more
Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene PanelsInvivoscribe Marketing2021-02-26T19:12:15-08:00May 9th, 2018|Read more
Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 MutationsInvivoscribe Marketing2021-02-26T19:12:23-08:00May 8th, 2018|Read more
Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Softwarewmm2021-02-26T19:12:40-08:00November 7th, 2017|Read more